Highlands Oncology Group, Fayetteville, Arkansas

Highlands Oncology Group
About Your Visit   Clinic Information   Clinic Location   Contact Us   Home
Imaging   Links   Massage   Patient Assistance   Patient Education   Physicians
Research   Staff   The Center for Chest Care   Treatment Info
RESEARCH CENTER -- 2008
J. Thaddeus Beck, MD, FACP, DIRECTOR OF RESEARCH
Research Staff, Highlands Oncology Group, Fayetteville, Arkansas
Highlands Oncology Group Research
Staff

Back Row
(left to right):
Lori Drummond
Anessa Conway
Amy Moore
Wendy Parnell
Kim Davison

Front Row:
Nina Jinks
Rachael Murphy
Becky Ivey
Vicki Weaver
 
Current Open Enrollment Clinical Trials

UPDATED May 5, 2008
       Blood / Bone Marrow
Novartis Z-MARK CZOL446EUS129: "Bone Marker Directed Dosing of ZOMETA (zoledronic acid) for the Prevention of Skeletal Complication in Patients with Advanced Multiple Myeloma."

Alexion (EXPLORE) P06-001: "Examination of PNH, by Level of CD59 on Red and White blood cells, in bone marrow failures syndromes."

       Breast
Novartis CRAD001J2101: "A Phase 1b Study Investigating the combination of RAD001 with Trastuzumab and Paclitaxel in patients with HER2-Overexpressing metastatic breast cancer."

SWOG SO226: "Phase III randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line for Post Menopausal Women with Metastatic Breast Cancer."

SWOG SO307: "Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer."

SWOG SO622: "Phase II Studies of Two different Schedules of Dasatinib (NSC-732517) In Bone Metastasis Predominant Metastatic Breast Cancer."

UARK 2004-19: "Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination with Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) subjects who Progressed on First Line Hormonal Therapy."

Acorn ACO1B07 "A double-blind, randomized phase 2b study of sorafenib compared to placebo when administered in combination with chemotherapy for patients with locally advanced or metastatic breast cancer that has progressed during or after bevacizumab therapy."

Breast NU 07B1 (Acorn/Onyx): "A double-Blind,Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer."

SWOG NCIC CTG: MA.17R: "A double blind re-randomization to Letrozole or placebo for women completing five years of adjuvant Letrozole."

Novartis CZOL446E2352: "A randomized, 3-Arm trial of the continued efficacy and safety of Zometa every 4 weeks vs. every 12 weeks vs. placebo in patients with documented bone metastases from breast cancer." -- ON HOLD

SWOG S2221: "Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer."

       Carcinoid
 
       Colo/Rectal
Pfizer A6181104: "A Randomized, Phase 3B study of Sunitinib plus Oxaliplatin, 5-Fluorouracil and Leucovorin (Folfox) versus Bevacizumab plus Folfox as first-line treatment in patients with metastatic Colorectal cancer."

Novartis CRAD001C2242: "An open-label, multicenter Phase I study investigating the combination on RAD001, Cetuximab and Irinotecan as second-line therapy after FOLFOX (or XELOX) plus Bevacizumab (if given as part of local standard practice) in patients with metastatic colorectal adenocarcinoma." -- ON HOLD

CTSU N0147: "A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer."
       Esophageal
SWOG S0356: "Oxaliplatin Plus Protracted Infusion 5-Fluorouracil and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial with Molecular Correlates."
       Lung
SWOG SO533: "A Pilot Trial of Cisplatin/Etoposide/Radiotherapy followed by consolidation Docetaxel and the addition of Bevacizumab (NSC-704865) in three Cohorts of patients with inoperable locally advanced stage III Non-Small Cell Lung Cancer."

Eli Lilly H6Q-MC-SO34: "Randomized, Double-Blind, Phase 2 study of Pemetrexed+Carboplatin+Bevacizumab+Enzastaurin versus Pemetrexed+Carboplatin+Bevacizumab+Placebo in chemonaive patients with stage IIIB or IV Non-Small Cell Lung Cancer."

AVAX A/100/0601 Phase I (NSCLC) L-VAX: "A feasibility study using a DNP-modified autologous tumor cell vaccine as therapy in patients with stage I or II Non-Small Cell Lung Cancer."

ABBOTT M05-780: "A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer."

AMGEN/ACORN 20060136: "A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination with Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer."

Lineberger Cancer CenterLCCC 0512: "Randomized Phase II Study of First-Line Treatment with Gemcitabine vs. Erlotinib vs. Gemcitabine and Erlotinib in Elderly Patients with Stage IIIB/IV Non-Small Cell Lung Cancer."

Genentech OSI3364g: "A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (Erlotinib) Compared with Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer After Failure of Standard First-Line Chemotherapy."

SWOG E5597: "A Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer."
       Lymphoma
Genentech Protocol APO3585g: "A Phase 1B/II, Open-Label, Multicenter study of the safety, pharmacokinetics, and efficacy of APO2L/Trial administered intravenously in combination with Reituximab to subjects with Follicular and other Low-Grade, CD20+, B-Cell Non-Hodgkin's Lymphomas that have progressed following previous Rituximab therapy."

       Melanoma
Genentech AVF4096g: "A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Carboplatin and Paclitaxel Chemotherapy for the First Line Treatment of Patients with Metastatic Melanoma."

       Pancreatic
   
       Prostate
SWOG SO354: "A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), In Patients With Hormone Refractory Prostate Cancer."

       Renal
SWOG E2805: "ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma."



To learn more about these Protocols please contact
Clinical Research Coordinator:  Wendy Parnell, R.N.
Highlands Oncology Research Center  PH: 479-872-8130
E-mail wparnell@hogonc.com
T O P
Copyright©2008 by
Highlands Oncology Group
All Rights Reserved.